RESUMO
Exposure to low temperatures can be considered a stressor, which when applied for a specific time can lead to adaptive reactions. In our study we hypothesized that cold, when applied to the entire body, may be a factor that positively modifies the aging process of bones by improving the mechanisms related to the body's mineral balance. Taking the above into account, the aim of the study was to determine the concentration of calcium (Ca), magnesium (Mg), and phosphorus (P) in bones, and to examine bone density and concentrations of the key hormones for bone metabolism, namely parathyroid hormone (PTH), somatotropin (GH), 1,25-dihydroxyvitamin D3, 17-ß estradiol, testosterone (T) in plasma, and prostaglandin E2 (PGE2) in the bone of aging rats subjected to physical training in cold water. The animals in the experiment were subjected to a series of swimming sessions for nine weeks. Study group animals (male and female respectively) performed swimming training in cold water at 5 ± 2 °C and in water with thermal comfort temperature (36 ± 2 °C). Control animals were kept in a sedentary condition. Immersion in cold water affects bone mineral metabolism in aging rats by changing the concentration of Ca, Mg, and P in the bone, altering bone mineral density and the concentration of key hormones involved in the regulation of bone mineral metabolism. The effect of cold-water immersion may be gender-dependent. In females, it decreases Ca and Mg content in bones while increasing bone density and 17-ß estradiol and 1,25-dihydroxyvitamin D3 levels, and with a longer perspective in aging animals may be positive not only for bone health but also other estrogen-dependent tissues. In males, cold water swimming decreased PTH and PGE2 which resulted in a decrease in phosphorus content in bones (with no effect on bone density), an increase in 1,25-dihydroxyvitamin D3, and increase in T and GH, and may have positive consequences especially in bones and muscle tissue for the prevention of elderly sarcopenia.
Assuntos
Envelhecimento/fisiologia , Crioterapia/métodos , Esforço Físico/fisiologia , Animais , Densidade Óssea/efeitos dos fármacos , Osso e Ossos/química , Calcitriol/análise , Calcitriol/sangue , Cálcio/análise , Temperatura Baixa , Dinoprostona/análise , Estradiol/análise , Estradiol/sangue , Feminino , Hormônio do Crescimento/análise , Hormônio do Crescimento/sangue , Magnésio/análise , Masculino , Hormônio Paratireóideo/análise , Hormônio Paratireóideo/sangue , Fósforo/análise , Condicionamento Físico Animal/métodos , Plasma/química , Ratos , Ratos Wistar , Testosterona/análise , Testosterona/sangueRESUMO
BACKGROUND: Surgery is currently the only treatment option for patients with primary hyperparathyroidism (PHPT). Recently, minimally invasive parathyroidectomy (MIP) has begun to replace traditional bilateral neck exploration (BNE). OBJECTIVE: The aim of this study is to compare the results of parathyroidectomies performed in our hospital over the past decade that were guided by intra-operative parathyroid hormone (IOPTH) sampling or frozen section (FS) analysis. MATERIAL AND METHODS: Data on 697 patients who underwent parathyroidectomies in the Department of Endocrine Surgery, Dokuz Eylul University between January 2005 and 2018 were included in this study. Patients with malignancies other than thyroid papillary microcarcinoma and parathyroid cancer were excluded from the study. RESULTS: The concomitant use of neck ultrasound (US) and technetium 99m Sestamibi (99mTc MIBI) scintigraphy successfully localized the hyperfunctioning parathyroid glands in nearly 96% of cases. As compared with the IOPTH group, the operation time was longer in the FS group (p < 0.001), and the need for postoperative calcium (Ca) supplementation was higher (p < 0.001). The duration of hospitalization (days) was significantly higher in the FS group (4.2 ± 3.4 vs. 2.6 ± 1.9) as compared with that in the IOPTH group (p < 0.001). In addition, the recurrence rate in the FS group was significantly higher than that in the IPOTH group (p = 0.002). CONCLUSION: IOPTH sampling is a safe and effective method when performed by experienced surgeons and with appropriate preoperative screening. This study emphasizes that IOPTH sampling. We believe that the success in parathyroid surgery is due to three factors: correct indication, accurate localization and experienced surgeon.
Assuntos
Secções Congeladas , Hiperparatireoidismo/diagnóstico , Hiperparatireoidismo/cirurgia , Procedimentos Cirúrgicos Minimamente Invasivos/métodos , Monitorização Intraoperatória/métodos , Hormônio Paratireóideo/análise , Paratireoidectomia/métodos , Adulto , Idoso , Feminino , Humanos , Hiperparatireoidismo/metabolismo , Hiperparatireoidismo/patologia , Tempo de Internação/estatística & dados numéricos , Masculino , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/epidemiologia , Duração da Cirurgia , Cintilografia , Cirurgia Assistida por Computador/métodos , Resultado do Tratamento , UltrassonografiaRESUMO
Background and objectives: Vitamin D is an essential vitamin that plays a key role in maintaining physiological calcium balance, and is also a pivotal element in the formation of bone structure. Vitamin D deficiency is associated with a wide array of clinical symptoms. Vitamin and mineral deficiencies are quite common prior to and after bariatric surgery, and therefore we have evaluated the effects of two different cholecalciferol supplementation regimes on serum calcium, 25(OH) cholecalciferol, and parathyroid hormone (PTH). Materials and Methods: In this retrospective matched cohort study, two different cholecalciferol supplementation regimes were compared. Group A consisted of 50 patients who had 1000 mg calcium and 800 IU cholecalciferol. In Group B, 50 patients had 1000 mg calcium and 800 IU cholecalciferol with an additional 1 ml liquid cholecalciferol (50,000 IU) monthly. The primary outcome was the effects on blood serum levels of calcium, 25(OH) cholecalciferol, and PTH. Results: In group A and group B, there were significant increases in 25(OH) cholecalciferol, with a higher delta in favor of group B (for all three p < 0.001). A decrease was seen in PTH (p < 0.001), and no differences were measured in calcium levels in both groups. Conclusion: Our study suggests that an additional 1 ml cholecalciferol (50,000 IU) monthly can result in less biochemically 25(OH) cholecalciferol deficient patients after bariatric surgery. No effects were seen on the calcium balance. However, larger randomized clinical trials need to be done to assess the effects on clinical outcomes like bone health and fracture risk.
Assuntos
Cirurgia Bariátrica/reabilitação , Cálcio/análise , Colecalciferol/uso terapêutico , Hormônio Paratireóideo/análise , Adulto , Análise de Variância , Cirurgia Bariátrica/métodos , Cálcio/sangue , Colecalciferol/farmacologia , Estudos de Coortes , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Países Baixos , Hormônio Paratireóideo/sangue , Projetos Piloto , Período Pós-Operatório , Estudos Retrospectivos , Vitamina D/análise , Vitamina D/sangueRESUMO
Antecedentes y objetivos: El déficit de 25(OH)D se ha relacionado con un riesgo cardiovascular aumentado, aunque los estudios de intervención son contradictorios. El objetivo principal fue evaluar el efecto del tratamiento con calcifediol (25(OH)D3) sobre el sistema cardiovascular en pacientes con síndrome coronario agudo sin elevación de segmento ST. Pacientes y método: Estudio prospectivo que incluyó a 41 pacientes (70,6±6,3 años) ≥60 años con síndrome coronario agudo sin elevación de segmento ST y enfermedad coronaria revascularizada percutáneamente. Se aleatorizaron a recibir calcifediol+tratamiento habitual o tratamiento habitual exclusivo, con evaluación de major adverse cardiovascular events (MACE, «episodios cardiovasculares mayores adversos») a los 3 meses. Se estudió la 25(OH)D en relación con otras variables analíticas y con la extensión de la enfermedad coronaria. Resultados: Niveles basales de 25(OH)D≤50nmol/l se asociaron a enfermedad coronaria multivaso (RR: 2,6 [IC 95%: 1,1-7,1], p=0,027) y 25(OH)D≤50nmol/l+paratohormona≥65pg/ml identificaron a pacientes con mayor riesgo de MACE (RR: 4 [IC 95%: 1,1-21,8], p=0,04). Se registró un MACE en el grupo de pacientes suplementados y 5 en el de tratamiento convencional (p=0,66). Entre los pacientes con niveles séricos de 25(OH)D≤50nmol/l al final del estudio el 28,6% presentaron MACE frente al 0% si los niveles eran>50nmol/l (RR: 1,4; p=0,037). Conclusiones: El déficit de vitamina D que implica un hiperparatiroidismo secundario puede ser un buen predictor de MACE. En pacientes suplementados con calcifediol se observó una tendencia a la disminución de MACE en el seguimiento. Niveles finales de 25(OH)D≤50nmol/l se asociaron significativamente a un mayor número de MACE, por lo que la normalización de 25(OH)D, además de mejorar la salud ósea, puede mejorar la salud cardiovascular
Background and objectives: Vitamin D deficiency has been consistently linked with cardiovascular diseases. However, results of intervention studies are contradictory. The aim of this study was to evaluate the effect of treatment with calcifediol (25(OH)D3) on the cardiovascular system of patients with non-ST-elevation acute coronary syndrome after percutaneous coronary intervention. Patients and methods: A prospective study assessing≥60-year-old patients with non-ST-elevation acute coronary syndrome, coronary artery disease and percutaneous revascularisation. We randomly assigned 41 patients (70.6±6.3 years) into 2 groups: Standard treatment+25(OH)D3 supplementation or standard treatment alone. Major adverse cardiovascular events (MACE) were evaluated at the conclusion of the 3-month follow-up period. 25(OH)D levels were analysed with regard to other relevant analytical variables and coronary disease extent. Results: Basal levels of 25(OH)D≤50nmol/L were associated with multivessel coronary artery disease (RR: 2.6 [CI 95%:1.1-7.1], P=.027) and 25(OH)D≤50nmol/L+parathormone ≥65pg/mL levels correlated with increased risk for MACE (RR: 4 [CI 95%: 1.1-21.8], P=.04]. One MACE was detected in the supplemented group versus five in the control group (P=.66). Among patients with 25(OH)D levels≤50nmol/L at the end of the study, 28.6% had MACE versus 0% among patients with 25(OH)D>50nmol/L (RR: 1,4; P=.037). Conclusions: Vitamin D deficiency plus secondary hyperparathyroidism may be an effective predictor of MACE. A trend throughout the follow up period towards a reduction in MACE among patients supplemented with 25(OH)D3 was detected. 25(OH)D levels≤50nmol/L at the end of the intervention period were significantly associated with an increased number of MACE, hence, 25(OH)D level normalisation could improve cardiovascular health in addition to bone health
Assuntos
Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Idoso , Hormônio Paratireóideo/análise , Calcifediol/deficiência , Deficiência de Vitamina D , Infarto do Miocárdio sem Supradesnível do Segmento ST/sangue , Intervenção Coronária Percutânea/métodos , Revascularização Miocárdica/métodos , Biomarcadores/análise , Hiperparatireoidismo Secundário , Estudos Prospectivos , Calcifediol/administração & dosagem , Calcifediol/uso terapêutico , Conservadores da Densidade Óssea , Infarto do Miocárdio sem Supradesnível do Segmento ST/tratamento farmacológico , Infarto do Miocárdio sem Supradesnível do Segmento ST/cirurgiaRESUMO
La suplementación con calcio reduciría, sola o asociada a otra medicación para osteoporosis, la pérdida de masa ósea y el riesgo de fracturas. Sin embargo, su tasa de adherencia es baja debido a la poca tolerancia. Objetivo: comparar la tasa de absorción neta de calcio entre dos formulaciones distintas de carbonato de calcio (500 mg): comprimidos vs. mousse. Material y métodos: 11 pruebas fueron realizadas en mujeres posmenopáusicas de 58,9±3 años. El diseño fue exploratorio abierto, aleatorizado, prospectivo cruzado de fase 4. Intervención: las participantes fueron aleatorizadas en dos grupos para recibir las dos formulaciones previa suplementación con vitamina D3. La tasa de absorción neta de calcio fue estudiada por la prueba de inhibición de hormona paratiroidea (PTH). Se obtuvieron muestras de sangre: basal y en la 1a, 2a y 3a hora posadministración del calcio asignado, y de orina de 2 horas basal y al final de la prueba. Determinaciones bioquímicas: calcio, fósforo, albúmina, 25-hidroxivitamina D y hormona paratiroidea intacta y calciuria. Análisis estadístico: método de los trapecios para calcular el área bajo la curva (AUC) de la concentración de calcio en el tiempo (R Development Core Team (2008). http://www.Rp-project.org) y Anova con dos términos de error para evaluar el efecto secuencia, período y formulación. Resultados: la mayor inhibición de PTH se observó a dos horas de la toma de ambas formulaciones (comprimidos -39,2% vs. mousse -38,0%; p=ns), con similar AUC0-3 h (comprimidos 3,35; IC 95%: 3,32; 3,37 vs. mousse 3,36; IC 95%: 3,33; 3,38). Cuando analizamos tolerancia y preferencias no se observaron diferencias estadísticamente significativas entre ambas formulaciones. Conclusión: el carbonato de calcio en mousse mostró similar tasa de absorción intestinal, preferencia y tolerancia gastrointestinal que en comprimido. (AU)
Calcium supplementation, administered alone or in combination with a specific medication for osteoporosis, would reduce bone mass loss and fracture risk in postmenopausal women. However, the adherence rate to calcium supplements is low, mainly due to low tolerance. Objective: comparisson of net calcium absorption rate between two different pharmaceutical formulations of calcium carbonate (PFCa) in postmenopausal women. Materials and Methods: 11 tests were performed in postmenopausal women aged 58.9±3 yrs. Design: Comparative, randomized, prospective, open-label exploratory crossover study of calcium mousse versus calcium pills. Intervention: Participants were randomized in 2 groups to receive the 2 different PFCa (500mg): pills vs. mousse, with previous vitamin D3 supplementation. The parathyroid hormone (PTH) inhibition test and the area-under-thecurve (AUC) of calcium were analyzed. Blood samples were taken at baseline and 1, 2 and 3 hrs after intake of the assigned PFCa. Urine samples (2hs) were obtained at -baseline, after 2hs of PFCa intake and at the end of the test. Biochemical Determinations: Serum: calcium, phosphorus, albumin, 25-hydroxyvitamin D, and intact PTH. In urine: calcium. Statistical Analysis: The trapezoid rule was applied to assess AUC in time (R Development Core Team (2008). http://www.Rp-project.org). An ANOVA model with 2 error terms was used to assess the effect of sequence, period, and formulation. Results: The highest inhibition PTH rates were observed after 2 hrs of PFCa (pills -39.2% vs. mousse -38.0%; p=ns). The AUC0-3hrs for both PFCa was similar (pills 3.35; 95%CI: 3.32; 3.37 vs. mousse 3.36; 95%CI: 3.33; 3.38). No statistically significant differences were observed when we analyze tolerance and predilection. Conclusion: The calcium carbonate in mousse showed an adequate rate of intestinal absorption, similarly predilection and gastrointestinal tolerance than the pill presentation. (AU)
Assuntos
Humanos , Feminino , Pessoa de Meia-Idade , Carbonato de Cálcio/farmacocinética , Osteoporose Pós-Menopausa/prevenção & controle , Cálcio/farmacocinética , Hormônio Paratireóideo/análise , Acloridria , Calcitriol/farmacocinética , Carbonato de Cálcio/administração & dosagem , Carbonato de Cálcio/uso terapêutico , Índice de Massa Corporal , Densidade Óssea , Avaliação Nutricional , Osteoporose Pós-Menopausa/dietoterapia , Osteoporose Pós-Menopausa/tratamento farmacológico , Programas de Rastreamento , Cálcio/deficiência , Pós-Menopausa/efeitos dos fármacos , Pós-Menopausa/sangue , Colecalciferol/administração & dosagem , Colecalciferol/efeitos adversos , Estudos Cross-Over , Citrato de Cálcio/uso terapêutico , Fraturas Ósseas/prevenção & controle , Estrogênios/deficiência , Absorção Gastrointestinal/efeitos dos fármacos , Cooperação e Adesão ao Tratamento , Anabolizantes/uso terapêuticoRESUMO
BACKGROUND The aim of this study was to investigate the optimal vitamin D status in the middle-aged and elderly population residing in Shanghai, China. MATERIAL AND METHODS A total of 1,829 males and postmenopausal females older than 45 years of age in the Changfeng community of Shanghai were included in this study. The optimal vitamin D level was determined according to the suppression of parathyroid hormone (PTH) and the highest bone mineral density (BMD). Locally weighted scatter plot smoothing (LOWESS) was performed to study the correlations of 25(OH)D with PTH and BMD in the lumbar spine and total hip, adjusting for gender, age, weight, use of calcium and vitamin D supplements, eGFR, smoking status, and alcohol consumption. RESULTS The mean serum 25(OH)D concentration was 48.0±19.2 nmol/L for the whole study population. The circulating PTH was maximally suppressed by the serum 25(OH)D of 55 nmol/L in the total population (60 nmol/L for males and 50 nmol/L for females). The 25(OH)D concentrations corresponding to the highest BMD at lumbar spine (L1-L4) and total hip were 53 nmol/L and 75 nmol/L, respectively, for the whole population. These values were also higher in males than females. CONCLUSIONS The optimal 25(OH)D concentration of 55 nmol/L is sufficient to maintain the bone health and metabolic status in middle-aged and elderly individuals living in Shanghai. Males probably need higher vitamin D concentration than females. There are differences between vitamin D status based on lumbar spine BMD and total hip BMD.
Assuntos
Densidade Óssea/efeitos dos fármacos , Vitamina D/metabolismo , Idoso , Idoso de 80 Anos ou mais , Osso e Ossos/efeitos dos fármacos , Cálcio/sangue , China , Suplementos Nutricionais , Feminino , Humanos , Vértebras Lombares , Masculino , Pessoa de Meia-Idade , Osteoporose Pós-Menopausa/tratamento farmacológico , Hormônio Paratireóideo/análise , Hormônio Paratireóideo/sangue , Hormônio Paratireóideo/metabolismo , Vitamina D/sangue , Deficiência de Vitamina D/sangue , VitaminasRESUMO
We report a case of transient neonatal hypercalcaemia secondary to excess maternal vitamin D intake in pregnancy. Vitamin D insufficiency and deficiency in pregnancy are associated with adverse pregnancy outcomes, but there is no definite benefit to supplementation. The Royal College of Obstetrics and Gynaecology recommends routine supplementation with vitamin D3 400 IU/day, but higher dose preparations usually recommended for the treatment of vitamin D deficiency are readily available over the counter. This case highlights the risks of excess supplementation, especially at higher doses and in women without evidence of vitamin D deficiency. The amount used in this case was at the upper end of the generally accepted safe dose range, but still less than that commonly recognised to cause problems. Neonatal hypercalcaemia is a potentially serious condition. The current local or national recommendations for vitamin D supplementation and the possible adverse effects of excess vitamin D consumption should be clearly communicated to pregnant women.
Assuntos
Cistos/patologia , Hipercalcemia/induzido quimicamente , Recém-Nascido/sangue , Deficiência de Vitamina D/tratamento farmacológico , Vitamina D/administração & dosagem , Vitamina D/efeitos adversos , Cistos/etiologia , Diagnóstico Diferencial , Suplementos Nutricionais , Feminino , Humanos , Hormônio Paratireóideo/análise , Gravidez , Complicações na Gravidez/tratamento farmacológico , Resultado da Gravidez , Resultado do Tratamento , Vagina/patologia , Vitamina D/análogos & derivados , Vitamina D/sangue , Vitamina D/uso terapêuticoRESUMO
Antecedentes: En la actualidad hay una elevada incidencia de pacientes ancianos con enfermedad renal crónica avanzada (ERCA), siendo importante conocer la evolución a largo plazo y qué factores influyen. Objetivos: Analizar la evolución de la ERCA en pacientes ancianos y la influencia del metabolismo óseo-mineral. Métodos: Estudio retrospectivo de 125 pacientes ≥70años con ERC 4-5, que iniciaron seguimiento desde el 1 de enero de 2007 al 31 de diciembre de 2008, observándose la progresión de la ERC (medida con la pendiente de la línea de regresión del filtrado glomerular estimado [FGe] obtenido mediante MDRD-4) durante 5años. Resultados: Progresión grupo completo (mediana y percentiles 25 y 75): -1,15 (-2,80/0,17) ml/min/1,73m2/año, ERC-4: -1,3 (-2,8/0,03) ml/min/1,73m2/año, ERC-5: -1,03 (-3/0,8) ml/min/1,73m2/año; pendiente de línea de regresión positiva en 35 pacientes (28%: ERC no progresa) y negativa 90 pacientes (72%: ERC progresa). Correlación (Spearman) negativa (progresión más lenta): hormona paratiroidea (PTH), albuminuria/Cr, excreción diaria de Na (todos basales). No se correlacionó con FGe, P sérico, excreción urinaria de P, ingesta proteica e ingesta de P (todas basales). Regresión lineal (variable dependiente: pendiente de progresión): albuminuria y PTH (ambos a nivel basal) influyeron de forma independiente en dicha variable. Regresión logística (progresa vs. no progresa): PTH, albuminuria y FGe (todos basales) influyeron de forma significativa. Conclusiones: En nuestro grupo de pacientes de edad avanzada el deterioro de la función renal es muy lento, especialmente en los pacientes en estadio5. La albuminuria y la PTH al inicio del seguimiento son factores pronósticos en la evolución de su función renal (AU)
Background: At present, there is a high incidence of elderly patients with advanced chronic kidney disease (CKD) and it is important to know the long term progression and the factors that influence it. Objectives: To analyse the progression of advanced CKD in elderly patients and the influence of bone-mineral metabolism. Methods: Retrospective study of 125 patients ≥70years of age with CKD stages 4-5 who started follow-up from January 1, 2007 to December 31, 2008, showing the progression of CKD (measured by the slope of the regression line of the estimated glomerular filtration rate [eGFR] by MDRD-4) over 5years. Results: Progression in the entire group (median and 25th and 75th percentiles): -1.15 (-2.8/0.17) ml/min/1.73m2/year, CKD-4: -1.3 (-2.8/0.03) ml/min/1.73m2/year, CKD-5: -1.03 (-3.0/0.8) ml/min/1.73m2/year; the slope of the regression line was positive in 35 patients (28%: CKD does not progress) and negative in 90 patients (72%: CKD progresses). Negative correlation (Spearman) (slower progression): PTH, albumin/Cr ratio and daily Na excretion (all baseline measurements). No correlation with eGFR, serum P, urinary P excretion, protein intake and intake of P (all baseline measurements). In the linear regression analysis (dependent variable: slope of progression): albuminuria and PTH (both at baseline measurements) influenced this variable independently. Logistic regression (progresses vs. does not progress): PTH, albuminuria and eGFR (all at baseline measurements) influenced significantly. Conclusions: In our group of elderly patients, impairment of renal function is slow, particularly in CKD-5 patients. Albuminuria and PTH at baseline levels are prognostic factors in the evolution of renal function (AU)
Assuntos
Humanos , Masculino , Feminino , Idoso , Idoso de 80 Anos ou mais , Hormônio Paratireóideo/análise , Insuficiência Renal Crônica/fisiopatologia , Albuminúria/diagnóstico , Fósforo/sangue , Progressão da Doença , Fatores de Risco , Biomarcadores/análise , Estudos Retrospectivos , Taxa de Filtração GlomerularRESUMO
OBJECTIVES: Anemia is an important prognostic factor in hemodialysis patients. It has been reported that parathyroidectomy ameliorates anemia and reduces the requirement of postoperative erythropoiesis-stimulating agents. The objective of this study was to assess the effect of cinacalcet, which is considered as a pharmacological parathyroidectomy, on anemia in hemodialysis patients. METHODS: We used data from a prospective cohort of Japanese hemodialysis patients with secondary hyperparathyroidism; the criteria were: intact parathyroid hormone concentrations ≥ 180 pg/mL or use of an intravenous or oral vitamin D receptor activator. All patients were cinacalcet-naïve at study enrollment. The main outcome measure was achievement of the target hemoglobin level (≥10.0 g/dL), which was measured repeatedly every 6 months. Cinacalcet exposure was defined as cumulative time since initiation. Both conventional longitudinal models and marginal structural models were adjusted for confounding factors. RESULTS: Among 3,201 cinacalcet-naïve individuals at baseline, cinacalcet was initiated in 1,337 individuals during the follow up. Cinacalcet users were slightly younger; included more patients with chronic glomerulonephritis and fewer with diabetes; were more likely to have a history of parathyroidectomy; and were more often on activated vitamin D agents, phosphate binders, and iron supplements. After adjusting for both time-invariant and time-varying potential confounders, including demographics, comorbidities, comedications, and laboratory values, each additional 6-month duration on cinacalcet was associated with a 1.1-fold increase in the odds of achieving the target hemoglobin level. CONCLUSIONS: Cinacalcet may improve anemia in chronic hemodialysis patients with secondary hyperparathyroidism, possibly through pathways both within and outside the parathyroid hormone pathways. Further investigations are warranted to delineate the roles of cinacalcet not only in the management of chronic kidney disease-mineral and bone disorder but also in anemia control.
Assuntos
Anemia/prevenção & controle , Calcimiméticos/uso terapêutico , Cinacalcete/uso terapêutico , Hiperparatireoidismo Secundário/tratamento farmacológico , Idoso , Calcitriol/análogos & derivados , Calcitriol/uso terapêutico , Estudos de Casos e Controles , Complicações do Diabetes/diagnóstico , Feminino , Seguimentos , Glomerulonefrite/complicações , Hemoglobinas/análise , Humanos , Hiperparatireoidismo Secundário/congênito , Falência Renal Crônica/complicações , Falência Renal Crônica/prevenção & controle , Masculino , Pessoa de Meia-Idade , Razão de Chances , Hormônio Paratireóideo/análise , Estudos Prospectivos , Receptores de Calcitriol/agonistas , Receptores de Calcitriol/metabolismo , Diálise Renal , Resultado do TratamentoRESUMO
UNLABELLED: Debilitating rickets-like lower limb deformities are common in children throughout the world, particularly in Malawi, Africa where the causes are unknown. We have identified that Blount disease and calcium deficiency rickets are the likely causes of these deformities and propose calcium supplementation as a potential treatment of Malawian rickets. INTRODUCTION: Surgical correction of rickets-like lower limb deformities is the most common paediatric operation performed at Beit Cure Orthopaedic Hospital, Malawi. The aim of this study was to investigate the aetiology of these deformities. METHODS: Children with a tibio-femoral angle of deformity >20° were enrolled (n = 42, 3.0-15.0 years). Anthropometric and early life and well-being data were collected. Early morning serum and urine samples were collected on the morning of the operation for markers of calcium and phosphate homeostasis. Knee radiographs were obtained, and the children were diagnosed with either Blount (BD, n = 22) or evidence of rickets disease (RD, n = 20). As BD is a mechanical rather than metabolic disease, BD were assumed to be biochemically representative of the local population and thus used as a local reference for RD. RESULTS: There were no differences in anthropometry or early life experiences between BD and RD. Parathyroid hormone (PTH), 1,25-dihydroxyvitamin D, total alkaline phosphatase and urinary phosphate were significantly higher and serum phosphate, 25-hydroxyvitamin D (25OHD) and tubular maximal reabsorption of phosphate significantly lower in RD than BD. There was no difference in serum calcium, fibroblast growth factor 23 or markers of iron status between groups. All children had 25OHD > 25 nmol/L. CONCLUSIONS: Vitamin D deficiency is not implicated in the aetiology of RD or BD in Malawian children. The cause of RD in Malawi is likely to be dietary calcium deficiency leading to elevated PTH resulting in increased losses of phosphate from the bone and glomerular filtrate. The causes of BD remain unclear; there was no evidence in support of previously suggested risk factors such as being overweight or starting to walk early. Prior to surgical intervention, supplementation with calcium should be considered for children with RD.
Assuntos
Doenças do Desenvolvimento Ósseo/etiologia , Extremidade Inferior/patologia , Osteocondrose/congênito , Raquitismo/etiologia , Fosfatase Alcalina/análise , Cálcio/análise , Criança , Pré-Escolar , Feminino , Humanos , Malaui/epidemiologia , Masculino , Osteocondrose/etiologia , Hormônio Paratireóideo/análise , Fosfatos/análise , Vitamina D/análogos & derivados , Vitamina D/análiseRESUMO
Parathyroid carcinoma is a malignant neoplasm affecting 0.5 to 5.0% of all patients suffering from primary hyperparathyroidism. This cancer continues to cause challenges for diagnosis and treatment because of its rarity, overlapping features with benign parathyroid disease, and lack of distinct characteristics. The third/second generation PTH assay ratio provides valuable information to distinguish between benign parathyroid disease and parathyroid carcinoma. An abnormal ratio (>1) could indicate a high suspicion regarding carcinoma and metastatic disease. Early en bloc surgical resection of the primary tumour with clear margins remains the best curative treatment. Although prolonged survival is possible with recurrent or metastatic disease, cure is rarely achievable. The efficacy of classical adjuvant therapies, such as radiotherapy and chemotherapy, in management of persistent, recurrent, or metastatic disease has been disappointing. In metastatic disease the goal of therapeutic support is to control the PTH-driven hypercalcemia that represents the primary cause of mortality. Calcimimetics, which are allosteric modulators of the calcium sensing receptor, have a sustained effect in lowering serum calcium levels. Bone anti-resorptive therapy, like intravenous bisphosphonates (pamidronate and zolendronate), or more recently denosumab (fully human monoclonal antibody with high affinity to bind RANK ligand) might be temporarily useful. In a small number of cases treated with anti-PTH immunotherapy, inducing anti-PTH antibodies, promising results have been seen with clinical improvements and decrease of calcemia. In one case metastasis shrinkage has been observed.
Assuntos
Neoplasias das Paratireoides/diagnóstico , Neoplasias das Paratireoides/terapia , Terapia Combinada , Humanos , Hiperparatireoidismo Primário/complicações , Estadiamento de Neoplasias , Hormônio Paratireóideo/análise , Neoplasias das Paratireoides/epidemiologia , Neoplasias das Paratireoides/cirurgia , Fatores de RiscoRESUMO
This paper illustrates the application of an antibody, anti-parathyroid hormone (anti-PTH), as a bioreceptor in a biosensor system for the first time, and demonstrates how this biosensor can be used in parathyroid hormone (PTH) determination. The interaction between the biosensor and parathyroid hormone was firstly investigated by a novel electrochemical method, single frequency impedance analysis. The biosensor was based on the gold electrode modified by cysteine self-assembled monolayers. Anti-PTH was covalently immobilized onto cysteine layer by using an EDC/NHS couple. The immobilization of anti-PTH was monitored by cyclic voltammetry and electrochemical impedance spectroscopy techniques. The performance of the biosensor was evaluated in terms of linearity, sensitivity, repeatability and reproducibility, after a few important optimization studies were carried out. In particular, parathyroid hormone was detected within a linear range of 10-60 fg/mL. Kramers-Kronig transform was also performed on the impedance data. The specificity of the biosensor was also evaluated. The biosensor was validated by using a complementary reference technique. Lastly the developed biosensor was used to monitor PTH levels in artificial serum samples.
Assuntos
Reações Antígeno-Anticorpo , Técnicas Biossensoriais , Espectroscopia Dielétrica/métodos , Anticorpos/química , Cisteína/química , Impedância Elétrica , Eletroquímica/métodos , Eletrodos , Ouro/química , Humanos , Oxirredução , Hormônio Paratireóideo/análise , Hormônio Paratireóideo/sangue , Reprodutibilidade dos Testes , Sensibilidade e EspecificidadeRESUMO
El presente estudio fue diseñado para evaluar la percepción actual de los nefrólogos españoles en el manejo clínico de las alteraciones del metabolismo óseo y mineral en la enfermedad renal crónica (CKD-MBD). Para ello se empleó un procedimiento semiestructurado de consenso profesional a distancia, por correo electrónico (método Delphi modificado), a un panel representativo del colectivo nefrológico, bajo la dirección de un comité coordinador. Para analizar la opinión grupal y el tipo de consenso alcanzado sobre cada cuestión planteada, se empleó la posición de la mediana de puntuaciones del grupo y el «nivel de concordancia» alcanzado por los encuestados. Sobre un total de 86 cuestiones se logró un consenso en acuerdo y desacuerdo en 70 (81,4 %), de los cuales un 60,5 % (52 ítems) lo fueron en términos de acuerdo con la aseveración y un 20,9 % (18 ítems) en desacuerdo. En 16 ítems (18,6 %) no se consiguió suficiente unanimidad de criterio en el panel, bien por disparidad de opinión profesional, bien por falta de criterio establecido en una mayoría del comité de expertos. Aceptando las limitaciones del estudio, consideramos que los ítems en los que hubo consenso refuerzan algunos conceptos de CKD-MBD con su repercusión en la práctica clínica diaria y permiten valorar el grado de homogeneidad que podríamos esperar en esta área. Los ítems en los que no hubo consenso nos ayudan a conocer las áreas de incertidumbre y resultan de gran utilidad para precisar en qué aspectos existe una mayor necesidad de profundización y de emprender estudios prospectivos que permitan mejorar el manejo de estas alteraciones (AU)
This study was designed to assess the current perception of Spanish nephrologists in the clinical management of mineral and bone metabolism disorders in chronic kidney disease (CKD-MBD). As such, we used a semi-structured distance professional consensus procedure via e-mail (modified Delphi method) on a representative nephrologist panel, under the direction of a coordinating committee. To analyse the group's opinion and the type of consensus reached on each issue raised, we used the median of the group's scores and the "level of agreement" reached by those surveyed. On a total of 86 issues, a consensus agreement and disagreement was achieved in 70 (81.4%), of which 60.5% (52 items) agreed with the statement and 20.9% (18 items) disagreed. In 16 items (18.6%), there was insufficient unanimity in the panel's opinion, either due to professional opinion disparity or due to the lack of opinion established in the majority of the expert committee. Accepting the study's limitations, we considered that the items for which there was a consensus reinforce some CKD-MBD concepts with their impact on daily clinical practice and allow the degree of homogeneity that we could expect in this area to be assessed. The items in which there was no consensus help us to know the areas of uncertainty and are very useful for clarifying which aspects have a greater need for further knowledge and which areas require prospective studies to be conducted to improve the management of these disorders (AU)
Assuntos
Humanos , Insuficiência Renal Crônica/complicações , Doenças Ósseas Metabólicas/epidemiologia , Calcimiméticos/uso terapêutico , Vitamina D/uso terapêutico , Hormônio Paratireóideo/análise , Cálcio/análise , Fósforo/análise , Minerais na Dieta/metabolismoRESUMO
BACKGROUND: To explore underlying molecular mechanisms in the pathogenesis of symptomatic sporadic primary hyperparathyroidism (PHPT). MATERIALS AND METHODS: Forty-one parathyroid adenomas from patients with symptomatic PHPT and ten normal parathyroid glands either from patients with PHPT (n=3) or from euthyroid patients without PHPT during thyroid surgery (n=7) were analyzed for vitamin D receptor (VDR), calcium-sensing receptor (CASR), cyclin D1 (CD1), and parathyroid hormone (PTH) expressions. The protein expressions were assessed semiquantitatively by immunohistochemistry, based on percentage of positive cells and staining intensity, and confirmed by quantitative real-time PCR. RESULTS: Immunohistochemistry revealed significant reductions in VDR (both nuclear and cytoplasmic) and CASR expressions and significant increases in CD1 and PTH expressions in adenomatous compared with normal parathyroid tissue. Consistent with immunohistochemistry findings, both VDR and CASR mRNAs were reduced by 0.36- and 0.45-fold change (P<0.001) and CD1 and PTH mRNAs were increased by 9.4- and 17.4-fold change respectively (P<0.001) in adenomatous parathyroid tissue. PTH mRNA correlated with plasma PTH (r=0.864; P<0.001), but not with adenoma weight, while CD1 mRNA correlated with adenoma weight (r=0.715; P<0.001). There were no correlations between VDR and CASR mRNA levels and serum Ca, plasma intact PTH, or 25-hydroxyvitamin D levels. In addition, there was no relationship between the decreases in VDR and CASR mRNA expressions and the increases in PTH and CD1 mRNA expressions. CONCLUSIONS: The expression of both VDR and CASR are reduced in symptomatic PHPT in Asian Indians. In addition, CD1 expression was greatly increased and correlated with adenoma weight, implying a potential role for CD1 in adenoma growth and differential clinical expression of PHPT.
Assuntos
Adenoma/química , Ciclina D1/análise , Hiperparatireoidismo Primário/metabolismo , Glândulas Paratireoides/química , Hormônio Paratireóideo/análise , Neoplasias das Paratireoides/química , Receptores de Calcitriol/análise , Receptores de Detecção de Cálcio/análise , População Branca , Adolescente , Adulto , Idoso , Criança , Ciclina D1/genética , DNA Complementar/síntese química , Feminino , Regulação Neoplásica da Expressão Gênica , Humanos , Imuno-Histoquímica , Índia , Masculino , Pessoa de Meia-Idade , Hormônio Paratireóideo/genética , RNA Mensageiro/análise , Reação em Cadeia da Polimerase em Tempo Real , Receptores de Calcitriol/genética , Receptores de Detecção de Cálcio/genética , Regulação para CimaRESUMO
Overall and cardiovascular mortality in patients with chronic kidney disease (CKD) is greatly increased, without obvious current effective treatments. Mineral and bone disorder (MBD) is a common manifestation of CKD and contributes to the high risk of fracture and cardiovascular mortality in these patients. Traditionally, clinical management of CKD-MBD focused on attenuation of secondary hyperparathyroidism due to impaired renal activation of vitamin D and phosphate retention, although recently, adynamic forms of renal bone disease have become more prevalent. Definitive diagnosis was based on histologic (histomorphometric) analysis of bone biopsy material supported by radiologic changes and changes in levels of surrogate laboratory markers. Of these various markers, parathyroid hormone (PTH) has been considered to be the most sensitive and currently is the most frequently used; however, the many pitfalls of measuring PTH in patients with CKD increasingly are appreciated. We propose an alternative or complementary approach using bone alkaline phosphatase (ALP), which is directly related to bone turnover, reflects bone histomorphometry, and predicts outcomes in hemodialysis patients. Here, we consider the overall merits of bone ALP as a marker of bone turnover in adults with CKD-MBD, examine published bone histomorphometric data comparing bone ALP to PTH, and discuss possible pathogenic mechanisms by which bone ALP may be linked to outcomes in patients with CKD.
Assuntos
Fosfatase Alcalina/análise , Doenças Ósseas/etiologia , Doenças Ósseas/metabolismo , Osso e Ossos/química , Insuficiência Renal Crônica/complicações , Insuficiência Renal Crônica/metabolismo , Biomarcadores/análise , Humanos , Minerais/metabolismo , Hormônio Paratireóideo/análiseRESUMO
BACKGROUND: More than 85% of primary hyperparathyroidism (PHPT) cases are due to solitary, benign parathyroid adenomas. Recently, the success rate of Tc99m sestamibi scintigraphy in localization has made minimally invasive parathyroidectomy (MIP) more prominent. MIP is as effective as conventional bilateral neck exploration. Moreover, it offers lower morbidity, cost effectiveness, and better cosmetics effects. AIM: We aimed to evaluate the success of MIP, which happens only under local anesthesia, in this study. MATERIALS AND METHODS: Total of 63 patients were operated for PHPT, of which 54 had solitary adenoma. Five patients underwent bilateral neck exploration under general anesthesia for thyroid nodules or unlocalizated adenomas. A total of 49 patients underwent MIP under local anesthesia without any sedation. During MIP, gamma probe was used for all patients. The patients were followed for parathyroid functions. RESULTS: The mean age of 49 patients with MIP (5 male, 44 female) was 59 years. The mean follow-up time was 16.4 (±10.1) months (range: 2-36 months). Of the 49 patients, 47 (96%) were totally cured. In 2 patients, the procedure was switched to conventional bilateral neck exploration. Temporary hypocalcaemia was noted in 4 patients. CONCLUSIONS: If the adenoma is localizated, MIP under only local anesthesia can be performed with a high success rate. Gamma probe-guided MIP under local anesthesia is an effective and safe method. It has the advantage of being minimally invasive and, therefore, it should be preferred over the conventional method.
Assuntos
Anestesia Local , Procedimentos Cirúrgicos Minimamente Invasivos/métodos , Glândulas Paratireoides/cirurgia , Neoplasias das Paratireoides/cirurgia , Paratireoidectomia , Adulto , Idoso , Feminino , Seguimentos , Humanos , Hiperparatireoidismo Primário/diagnóstico , Hiperparatireoidismo Primário/cirurgia , Hipocalcemia/diagnóstico , Masculino , Pessoa de Meia-Idade , Glândulas Paratireoides/diagnóstico por imagem , Hormônio Paratireóideo/análise , Neoplasias das Paratireoides/diagnóstico , Cintilografia , Resultado do Tratamento , Adulto JovemRESUMO
OBJECTIVE: To determine the influence of maximal androgen blockade (MAB) on bone mineral density (BMD) in men with prostate cancer. METHODS: We enrolled 40 men with prostate cancer treated by MAB for 7 to 12 months. We obtained the laboratory results of PSA, testosterone, serum calcium and phosphorus, 24-h urine calcium and phosphorus, alkaline phosphatase, and parathyroid hormone, measured the BMD of the lumbar spine and femoral neck by dual energy X-ray absorptiometry, recorded pain scores, and compared the results before and after the treatment. RESULTS: Before MAB treatment, 5 (12.5%) of the patients met the BMD criteria of lumbar spine (L2-4) osteopenia, 8 (20%) lumbar spine (L2-4) osteoporosis, 13 (32.5%) left femoral neck osteopenia, and 15 (37.5%) left femoral neck osteoporosis. The PSA and testosterone levels were decreased from (52.9 +/- 69.9) microg/L and (18.9 +/- 6.5) nmol/L before MAB to (1.5 +/- 1.6) microg/L and (1.9 +/- 1.3) nmol/L after it (P<0.05). There were no statistically significant differences before and after MAB in the levels of serum calcium and phosphorus, 24-h urine calcium and phosphorus, alkaline phosphatase, and parathyroid hormone (P>0.05), nor in the BMD levels of the lumbar spine ([1.1 +/- 0.1] vs [1.1 +/- 0.2] g/cm2) and femoral neck ([0.8 +/- 0.2] vs [0.8 +/- 0.1] g/cm2), nor in the pain score ([0.6 +/- 0.2] vs [0.7 +/- 0.1], P>0.05). CONCLUSION: MAB treatment (range from 7 to 12 months) has no significant influence on BMD in men with prostate cancer, but BMD should be measured before MAB.
Assuntos
Antagonistas de Androgênios/uso terapêutico , Densidade Óssea/efeitos dos fármacos , Neoplasias da Próstata/tratamento farmacológico , Idoso , Idoso de 80 Anos ou mais , Fosfatase Alcalina/análise , Antagonistas de Androgênios/administração & dosagem , Antagonistas de Androgênios/efeitos adversos , Doenças Ósseas Metabólicas/etiologia , Cálcio/sangue , Cálcio/urina , Humanos , Masculino , Pessoa de Meia-Idade , Osteoporose/etiologia , Hormônio Paratireóideo/análise , Fósforo/urina , Neoplasias da Próstata/metabolismo , Testosterona/sangueRESUMO
OBJECTIVE: To provide a clinical update on the management of hypoparathyroidism with focus on postsurgical hypoparathyroidism. METHODS: Using PubMed, English-language literature was searched related to management of hypoparathyroidism after thyroid and parathyroid surgery. We discuss the incidence, pathophysiology, differential diagnosis, early diagnosis, and treatment of transient and permanent hypoparathyroidism. RESULTS: Hypoparathyroidism is a well-recognized complication after thyroid and parathyroid surgery. Transient hypoparathyroidism occurs in 10% of patients who undergo total thyroidectomy. Less than half of patients who develop transient hypoparathyroidism after thyroid surgery develop permanent hypoparathyroidism. Postsurgical hypocalcemia resulting from inadequate parathyroid hormone (PTH) secretion could cause neurologic complications and respiratory compromise. Calcium supplements and vitamin D analogues effectively treat hypocalcemia associated with postsurgical hypoparathyroidism. Measurement of PTH after thyroid and parathyroid surgery allows early identification of patients likely to require calcium supplements and vitamin D analogue therapy. Early identification and appropriate management of postsurgical hypoparathyroidism prevent hypocalcemia-related complications and allow patients to be discharged from the hospital earlier. Patients who develop permanent hypoparathyroidism should receive appropriate follow-up care to monitor for long-term complications related to supplemental therapy. PTH replacement therapy is currently being evaluated for the treatment of transient and permanent hypoparathyroidism. CONCLUSIONS: A multidisciplinary approach involving an endocrinologist and surgeon is imperative to reduce the morbidity associated with hypoparathyroidism after thyroid and parathyroid surgery. Supplemental therapy with calcium and vitamin D analogues is standard. New drugs currently in clinical trials offer promising treatment options.
Assuntos
Hipoparatireoidismo/diagnóstico , Cálcio/uso terapêutico , Humanos , Hipoparatireoidismo/tratamento farmacológico , Hipoparatireoidismo/etiologia , Hipoparatireoidismo/cirurgia , Hormônio Paratireóideo/análise , Complicações Pós-Operatórias/diagnóstico , Complicações Pós-Operatórias/tratamento farmacológico , Complicações Pós-Operatórias/etiologia , Complicações Pós-Operatórias/cirurgia , Tireoidectomia/efeitos adversos , Vitamina D/uso terapêuticoRESUMO
OBJECTIVE: To evaluate the role of parathyroid hormone (PTH) and serum calcium in prediction for hypocalcaemia after total thyroidectomy. METHODS: One hundred and sixty-five patients undergoing total or complete total thyroidectomy were reviewed retrospectively. The indications included bilateral carcinoma, undifferential carcinoma, surroundings invasion, distant metastasis and huge benign lesions. Preoperative and postoperative PTH, calcium concentrations and their decline levels were compared between Jan. 2005 and May 2009. The role of PTH value and decline level predicting for symptomatic hypocalcaemia were analyzed by receiver operator characteristics (ROC) curve. RESULTS: After total thyroidectomy, 85 patients (51.5%) developed hypocalcemia. Symptoms were reported by 36 patients (21.8%). The mean concentration of PTH for normocalcaemia (80 cases), asymptomatic hypocalcaemia (49 cases) and symptomatic patients (36 cases) were 31.0 ng/L, 19.6 ng/L and 11.9 ng/L, respectively. The mean decline level for the three groups were 28.6%, 52.6% and 78.0%, respectively. PTH value and its decline level had a poor predicting value for symptomatic hypocalcaemia and high negative predicting value for asymptomatic patients. The serum calcium concentration more than 2.0 mmol/L, PTH level higher than 15 ng/L and PTH decline less than 50% had the good negative predicting value of 97.6%, 90.3% and 96.5%, respectively. CONCLUSIONS: Postoperative PTH and its decline level were significantly correlated with postoperative serum calcium concentration but had a low accuracy for predicting symptomatic hypocalcaemia. The serum calcium concentration more than 2.0 mmol/L, PTH level higher than 15 ng/L and PTH decline less than 50% had the good predicting value for asymptomatic patients. Calcium should be routinely supplemented in the first 24 h after total thyroidectomy to reduce the rate of hypocalcemia and the severity of hypocalcemia symptoms.
Assuntos
Cálcio/sangue , Hipocalcemia/diagnóstico , Hormônio Paratireóideo/análise , Tireoidectomia/efeitos adversos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Feminino , Humanos , Hipocalcemia/sangue , Masculino , Pessoa de Meia-Idade , Período Pós-Operatório , Estudos Retrospectivos , Neoplasias da Glândula Tireoide/cirurgia , Adulto JovemRESUMO
In this study, the relation between osteoporosis and vitamin D and the disease activity in patients with ankylosing spondylitis (AS) was investigated. A hundred patients with AS and 58 healthy individuals were included in the study. In addition to the routine blood and urine tests, serum 25-(OH)D3, parathormone (PTH), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), total calcium, ionized calcium, and phosphorous levels of all participants were also measured. Bone mineral density (BMD) measurements were performed at the anterior-posterior and lateral lumbar and femur regions. Anterior-posterior and lateral thoracic and lumbosacral radiography was performed on all participants. The disease activity was evaluated by Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), functional status by Bath Ankylosing Spondylitis Functional Index (BASFI), and mobility by Bath Ankylosing Spondylitis Metrology Index (BASMI). In the patient group, BMD values obtained from the lateral lumbar and femur regions and serum vitamin D levels were lower than the control group. A negative relation was determined between the lateral lumbar BMD values and ESR, CRP, and BASDAI scores of patients with AS. The ESR, CRP levels, and BASMI scores of the AS patients with osteoporosis were significantly higher, when compared to patients without osteoporosis. The negative correlation between serum 25-(OH)D3 level and ESR, CRP levels did not reach a statistically significant level in patients with AS; the positive correlation between PTH levels and ESR, and the negative correlation between CRP and BASDAI also did not reach a statistically significant level. Vitamin D deficiency in AS may indirectly lead to osteoporosis by causing an increase in the inflammatory activity. The present authors believe that it would be beneficial to monitorize vitamin D levels together with BMD measurements in order to determine the patients under osteoporosis risk.